Archives

Earlier this year Ashtons were consulted by the EU Exit Team, which is part of the Commercial Directorate of the Department of Health & Social Care (DHSC), regarding the preparations that we [...]

Cariprazine (Reagila) is a new second-generation antipsychotic which is licensed to treat schizophrenia in adults (over 18 years). It is only available as an oral capsule and is presented in [...]

The Food Standards Agency (FSA) has launched a publicity campaign to warn consumers about the health risks of using dietary products commonly known as ‘fat burners’ which are mainly obtained via [...]

What is the current risk of shortages for medicines and medical products due to Brexit? Should there be a no-deal Brexit, then there may be shortages of some medicines and other products due to [...]

A new formulation of clozapine will be available from June 2019 consisting of an oral dispersible tablet marketed as Zaponex orodispersible tablets by the company Leyden Delta BV. The special [...]

Buprenorphine has been long-established as an opioid substitution medication available as sublingual tablets. It is an opioid partial agonist/antagonist with strong receptor binding affinity and [...]

Lord Carter of Coles had led a review of NHS mental health and community health services to identify areas for improvement. These services account for about £17 billion of expenditure in England, [...]

Falsified medicines include counterfeit and unauthorised medicines and these can pose a health risk for patients. They are often disguised as authentic medicines and may be impossible to detect [...]

Prescriptions for Controlled Drugs (Schedule 2 and 3) can only be dispensed legally if the prescription contains all the mandatory requirements specified in the Misuse of Drugs Regulations 2001. [...]

Private prescriptions for Schedule 2 or 3 Controlled Drugs (CDs) that are dispensed by community pharmacies must be written on designated forms. In England, prescribers can now only order [...]